Bioengineering (Feb 2024)

The Humanization and Maturation of an Anti-PrPc Antibody

  • Cheng Zhang,
  • Fanlei Ran,
  • Lei Du,
  • Xiaohui Wang,
  • Lei Liu,
  • Jinming Liu,
  • Quan Chen,
  • Yang Cao,
  • Lijun Bi,
  • Haiying Hang

DOI
https://doi.org/10.3390/bioengineering11030242
Journal volume & issue
Vol. 11, no. 3
p. 242

Abstract

Read online

The cellular prion protein (PrPc) is a cell surface glycoprotein that is highly expressed in a variety of cancer tissues in addition to the nervous system, and its elevated expression is correlated to poor prognosis in many cancer patients. Our team previously found that patients with colorectal cancer (CRC) with high-level PrPc expression had significantly poorer survival than those with no or low-level PrPc expression. Mouse antibodies for PrPc inhibited tumor initiation and liver metastasis of PrPc-positive human CRC cells in mouse model experiments. PrPc is a candidate target for CRC therapy. In this study, we newly cloned a mouse anti-PrPc antibody (Clone 6) and humanized it, then affinity-matured this antibody using a CHO cell display with a peptide antigen and full-length PrPc, respectively. We obtained two humanized antibody clones with affinities toward a full-length PrPc of about 10- and 100-fold of that of the original antibody. The two humanized antibodies bound to the PrPc displayed significantly better on the cell surface than Clone 6. Used for Western blotting and immunohistochemistry, the humanized antibody with the highest affinity is superior to the two most frequently used commercial antibodies (8H4 and 3F4). The two new antibodies have the potential to be developed as useful reagents for PrPc detection and even therapeutic antibodies targeting PrPc-positive cancers.

Keywords